

# Alan W Partin

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/10661753/publications.pdf>

Version: 2024-02-01

356  
papers

38,109  
citations

3334

91  
h-index

3182

186  
g-index

359  
all docs

359  
docs citations

359  
times ranked

20086  
citing authors

#	ARTICLE	IF	CITATIONS
1	Risk of Prostate Cancer–Specific Mortality Following Biochemical Recurrence After Radical Prostatectomy. <i>JAMA - Journal of the American Medical Association</i> , 2005, 294, 433.	7.4	1,186
2	The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer. <i>Journal of Urology</i> , 1993, 150, 110-114.	0.4	1,152
3	Combination of Prostate-Specific Antigen, Clinical Stage, and Gleason Score to Predict Pathological Stage of Localized Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 1997, 277, 1445.	7.4	1,060
4	Use of the Percentage of Free Prostate-Specific Antigen to Enhance Differentiation of Prostate Cancer From Benign Prostatic Disease. <i>JAMA - Journal of the American Medical Association</i> , 1998, 279, 1542.	7.4	990
5	Contemporary update of prostate cancer staging nomograms (Partin Tables) for the new millennium. <i>Urology</i> , 2001, 58, 843-848.	1.0	943
6	LONG-TERM BIOCHEMICAL DISEASE-FREE AND CANCER-SPECIFIC SURVIVAL FOLLOWING ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY. <i>Urologic Clinics of North America</i> , 2001, 28, 555-565.	1.8	939
7	Ligand-Independent Androgen Receptor Variants Derived from Splicing of Cryptic Exons Signify Hormone-Refractory Prostate Cancer. <i>Cancer Research</i> , 2009, 69, 16-22.	0.9	939
8	Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. <i>Nature Genetics</i> , 2007, 39, 631-637.	21.4	818
9	Biochemical (Prostate Specific Antigen) Recurrence Probability Following Radical Prostatectomy for Clinically Localized Prostate Cancer. <i>Journal of Urology</i> , 2003, 169, 517-523.	0.4	691
10	Cancer Control and Quality of Life Following Anatomical Radical Retropubic Prostatectomy: Results at 10 Years. <i>Journal of Urology</i> , 1994, 152, 1831-1836.	0.4	650
11	Prostate Cancer–Specific Survival Following Salvage Radiotherapy vs Observation in Men With Biochemical Recurrence After Radical Prostatectomy. <i>JAMA - Journal of the American Medical Association</i> , 2008, 299, 2760.	7.4	586
12	Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy. <i>Journal of Urology</i> , 2011, 185, 869-875.	0.4	574
13	Prostate Specific Antigen in the Staging of Localized Prostate Cancer: Influence of Tumor Differentiation, Tumor Volume and Benign Hyperplasia. <i>Journal of Urology</i> , 1990, 143, 747-752.	0.4	568
14	Germline Mutations in <i>HOXB13</i> and Prostate-Cancer Risk. <i>New England Journal of Medicine</i> , 2012, 366, 141-149.	27.0	566
15	Active Surveillance Program for Prostate Cancer: An Update of the Johns Hopkins Experience. <i>Journal of Clinical Oncology</i> , 2011, 29, 2185-2190.	1.6	545
16	PROSTATE-SPECIFIC ANTIGEN AFTER ANATOMIC RADICAL RETROPUBIC PROSTATECTOMY. <i>Urologic Clinics of North America</i> , 1997, 24, 395-406.	1.8	542
17	Prognostic Gleason grade grouping: data based on the modified Gleason scoring system. <i>BJU International</i> , 2013, 111, 753-760.	2.5	540
18	Prediction of Progression Following Radical Prostatectomy. <i>American Journal of Surgical Pathology</i> , 1996, 20, 286-292.	3.7	532

#	ARTICLE	IF	CITATIONS
19	PROSTATE SPECIFIC ANTIGEN: A DECADE OF DISCOVERY-WHAT WE HAVE LEARNED AND WHERE WE ARE GOING. <i>Journal of Urology</i> , 1999, 162, 293-306.	0.4	530
20	SERUM PSA AFTER ANATOMIC RADICAL PROSTATECTOMY. <i>Urologic Clinics of North America</i> , 1993, 20, 713-725.	1.8	451
21	Updated Nomogram to Predict Pathologic Stage of Prostate Cancer Given Prostate-Specific Antigen Level, Clinical Stage, and Biopsy Gleason Score (Partin Tables) Based on Cases from 2000 to 2005. <i>Urology</i> , 2007, 69, 1095-1101.	1.0	410
22	A Multicenter Study of [-2]Pro-Prostate Specific Antigen Combined With Prostate Specific Antigen and Free Prostate Specific Antigen for Prostate Cancer Detection in the 2.0 to 10.0 ng/ml Prostate Specific Antigen Range. <i>Journal of Urology</i> , 2011, 185, 1650-1655.	0.4	408
23	A meta-analysis of 87,040 individuals identifies 23 new susceptibility loci for prostate cancer. <i>Nature Genetics</i> , 2014, 46, 1103-1109.	21.4	408
24	PCA3: A Molecular Urine Assay for Predicting Prostate Biopsy Outcome. <i>Journal of Urology</i> , 2008, 179, 1587-1592.	0.4	404
25	Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases. <i>Urology</i> , 1994, 43, 649-659.	1.0	376
26	The Clinical Usefulness of Prostate Specific Antigen: Update 1994. <i>Journal of Urology</i> , 1994, 152, 1358-1368.	0.4	372
27	Effect of Testosterone Replacement Therapy on Prostate Tissue in Men With Late-Onset Hypogonadism. <i>JAMA - Journal of the American Medical Association</i> , 2006, 296, 2351.	7.4	360
28	Common sequence variants on 2p15 and Xp11.22 confer susceptibility to prostate cancer. <i>Nature Genetics</i> , 2008, 40, 281-283.	21.4	357
29	An updated prostate cancer staging nomogram (<sc>P</sc>artin tables) based on cases from 2006 to 2011. <i>BJU International</i> , 2013, 111, 22-29.	2.5	323
30	Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. <i>Nature Genetics</i> , 2002, 32, 321-325.	21.4	318
31	Is Tumor Volume an Independent Predictor of Progression Following Radical Prostatectomy? A Multivariate Analysis of 185 Clinical Stage B Adenocarcinomas of the Prostate with 5 Years of Followup. <i>Journal of Urology</i> , 1993, 149, 1478-1481.	0.4	314
32	PTEN Protein Loss by Immunostaining: Analytic Validation and Prognostic Indicator for a High Risk Surgical Cohort of Prostate Cancer Patients. <i>Clinical Cancer Research</i> , 2011, 17, 6563-6573.	7.0	309
33	Prognostic significance of Gleason score 3+4 versus Gleason score 4+3 tumor at radical prostatectomy. <i>Urology</i> , 2000, 56, 823-827.	1.0	298
34	Obesity-Related Plasma Hemodilution and PSA Concentration Among Men With Prostate Cancer. <i>JAMA - Journal of the American Medical Association</i> , 2007, 298, 2275.	7.4	291
35	Metabolic Factors Associated with Benign Prostatic Hyperplasia. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2006, 91, 2562-2568.	3.6	281
36	Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. <i>Urology</i> , 2000, 56, 255-260.	1.0	275

#	ARTICLE	IF	CITATIONS
37	Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer. <i>Journal of Urology</i> , 2003, 169, 517-23.	0.4	271
38	Human Kallikrein 2 (hK2) and Prostate-Specific Antigen (PSA): Two Closely Related, but Distinct, Kallikreins in the Prostate. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 1998, 35, 275-368.	6.1	269
39	Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death. <i>European Urology</i> , 2017, 71, 740-747.	1.9	256
40	Prostate-Specific Antigen Kinetics During Follow-Up Are an Unreliable Trigger for Intervention in a Prostate Cancer Surveillance Program. <i>Journal of Clinical Oncology</i> , 2010, 28, 2810-2816.	1.6	237
41	Two Genome-wide Association Studies of Aggressive Prostate Cancer Implicate Putative Prostate Tumor Suppressor Gene DAB2IP. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1836-1844.	6.3	235
42	Can Urinary PCA3 Supplement PSA in the Early Detection of Prostate Cancer?. <i>Journal of Clinical Oncology</i> , 2014, 32, 4066-4072.	1.6	234
43	The Prostate Health Index Selectively Identifies Clinically Significant Prostate Cancer. <i>Journal of Urology</i> , 2015, 193, 1163-1169.	0.4	228
44	Analysis of percent free prostate-specific antigen (PSA) for prostate cancer detection: Influence of total psa, prostate volume, and age. <i>Urology</i> , 1996, 48, 55-61.	1.0	226
45	The natural history of metastatic progression in men with prostate-specific antigen recurrence after radical prostatectomy: long-term follow-up. <i>BJU International</i> , 2012, 109, 32-39.	2.5	221
46	African American Men With Very Low-Risk Prostate Cancer Exhibit Adverse Oncologic Outcomes After Radical Prostatectomy: Should Active Surveillance Still Be an Option for Them?. <i>Journal of Clinical Oncology</i> , 2013, 31, 2991-2997.	1.6	220
47	Characteristics of insignificant clinical T1c prostate tumors. <i>Cancer</i> , 2004, 101, 2001-2005.	4.1	213
48	Tissue-based Genomics Augments Post-prostatectomy Risk Stratification in a Natural History Cohort of Intermediate- and High-Risk Men. <i>European Urology</i> , 2016, 69, 157-165.	1.9	206
49	INTERPRETATION OF FREE PROSTATE SPECIFIC ANTIGEN CLINICAL RESEARCH STUDIES FOR THE DETECTION OF PROSTATE CANCER. <i>Journal of Urology</i> , 1998, 159, 5-12.	0.4	204
50	LONG-TERM RESULTS OF RADIATION THERAPY FOR PROSTATE CANCER RECURRENCE FOLLOWING RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 1998, 159, 173-178.	0.4	200
51	Preoperative Serum DNA GSTP1 CpG Island Hypermethylation and the Risk of Early Prostate-Specific Antigen Recurrence Following Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2005, 11, 4037-4043.	7.0	198
52	OA-519 (fatty acid synthase) as an independent predictor of pathologic stage in adenocarcinoma of the prostate. <i>Urology</i> , 1995, 45, 81-86.	1.0	196
53	Clinical Validation of an Epigenetic Assay to Predict Negative Histopathological Results in Repeat Prostate Biopsies. <i>Journal of Urology</i> , 2014, 192, 1081-1087.	0.4	196
54	The Prognostic Significance of Tertiary Gleason Patterns of Higher Grade in Radical Prostatectomy Specimens. <i>American Journal of Surgical Pathology</i> , 2000, 24, 563-569.	3.7	195

#	ARTICLE	IF	CITATIONS
55	Profiling the Urinary Microbiome in Men with Positive versus Negative Biopsies for Prostate Cancer. <i>Journal of Urology</i> , 2018, 199, 161-171.	0.4	188
56	A Prospective, Multicenter, National Cancer Institute Early Detection Research Network Study of [â²]proPSA: Improving Prostate Cancer Detection and Correlating with Cancer Aggressiveness. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 1193-1200.	2.5	186
57	Biomarkers for Prostate Cancer. <i>Annual Review of Medicine</i> , 2009, 60, 139-151.	12.2	180
58	<sup>18</sup>F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. <i>Journal of Nuclear Medicine</i> , 2015, 56, 1003-1010.	5.0	180
59	Selection of men at high risk for disease recurrence for experimental adjuvant therapy following radical prostatectomy. <i>Urology</i> , 1995, 45, 831-838.	1.0	179
60	Tumor angiogenesis correlates with progression after radical prostatectomy but not with pathologic stage in gleason sum 5 to 7 adenocarcinoma of the prostate. , 1997, 79, 772-779.		179
61	Death in Patients With Recurrent Prostate Cancer After Radical Prostatectomy: Prostate-Specific Antigen Doubling Time Subgroups and Their Associated Contributions to All-Cause Mortality. <i>Journal of Clinical Oncology</i> , 2007, 25, 1765-1771.	1.6	177
62	Free prostate-specific antigen in serum is becoming more complex. <i>Urology</i> , 2002, 59, 797-802.	1.0	174
63	Morphometric Measurement of Tumor Volume and Per Cent of Gland Involvement as Predictors of Pathological Stage in Clinical Stage B Prostate Cancer. <i>Journal of Urology</i> , 1989, 141, 341-345.	0.4	168
64	Gleason Score 6 Adenocarcinoma: Should It Be Labeled As Cancer?. <i>Journal of Clinical Oncology</i> , 2012, 30, 4294-4296.	1.6	162
65	Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. <i>European Urology</i> , 2009, 56, 659-668.	1.9	161
66	VALIDATION OF PARTIN TABLES FOR PREDICTING PATHOLOGICAL STAGE OF CLINICALLY LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2000, 164, 1591-1595.	0.4	160
67	Evidence for two independent prostate cancer riskâ€“associated loci in the HNF1B gene at 17q12. <i>Nature Genetics</i> , 2008, 40, 1153-1155.	21.4	158
68	Partial Nephrectomy: Technique Complications and Pathological Findings. <i>Journal of Urology</i> , 1995, 154, 1312-1318.	0.4	156
69	Adenocarcinoma of the prostate invading the seminal vesicle: prognostic stratification based on pathologic parameters. <i>Urology</i> , 2000, 56, 283-288.	1.0	148
70	Radical prostatectomy for clinical stage T3a disease. <i>Cancer</i> , 2007, 109, 1273-1278.	4.1	140
71	COMPLEXED PROSTATE SPECIFIC ANTIGEN PROVIDES SIGNIFICANT ENHANCEMENT OF SPECIFICITY COMPARED WITH TOTAL PROSTATE SPECIFIC ANTIGEN FOR DETECTING PROSTATE CANCER. <i>Journal of Urology</i> , 2000, 163, 1476-1480.	0.4	137
72	Heredity and prostate cancer: A study of World War II veteran twins. , 1997, 33, 240-245.		134

#	ARTICLE	IF	CITATIONS
73	An Evaluation of the Decreasing Incidence of Positive Surgical Margins in a Large Retropubic Prostatectomy Series. <i>Journal of Urology</i> , 2004, 171, 23-26.	0.4	133
74	EFFECTS OF A SAW PALMETTO HERBAL BLEND IN MEN WITH SYMPTOMATIC BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 2000, 163, 1451-1456.	0.4	128
75	Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. <i>Urology</i> , 1999, 54, 839-845.	1.0	126
76	Association Between Two Unlinked Loci at 8q24 and Prostate Cancer Risk Among European Americans. <i>Journal of the National Cancer Institute</i> , 2007, 99, 1525-1533.	6.3	126
77	Influence of age and prostate-specific antigen on the chance of curable prostate cancer among men with nonpalpable disease. <i>Urology</i> , 1999, 53, 126-130.	1.0	123
78	Accuracy of PCA3 Measurement in Predicting Short-Term Biopsy Progression in an Active Surveillance Program. <i>Journal of Urology</i> , 2010, 183, 534-538.	0.4	119
79	Use of percentage of free prostate-specific antigen to identify men at high risk of prostate cancer when psa levels are 2.51 to 4 ng/mL and digital rectal examination is not suspicious for prostate cancer: an alternative model. <i>Urology</i> , 1999, 54, 220-224.	1.0	117
80	Long-term cancer control of radical prostatectomy in men younger than 50 years of age: update 2003. <i>Urology</i> , 2003, 62, 86-91.	1.0	117
81	Association of [math>\hat{2}]proPSA with Biopsy Reclassification During Active Surveillance for Prostate Cancer. <i>Journal of Urology</i> , 2012, 188, 1131-1136.	0.4	115
82	Initial Prostate Biopsy: Development and Internal Validation of a Biopsy-specific Nomogram Based on the Prostate Cancer Antigen 3 Assay. <i>European Urology</i> , 2013, 63, 201-209.	1.9	114
83	Time to Prostate Specific Antigen Recurrence After Radical Prostatectomy and Risk of Prostate Cancer Specific Mortality. <i>Journal of Urology</i> , 2006, 176, 1404-1408.	0.4	110
84	Complexed Prostate Specific Antigen Improves Specificity for Prostate Cancer Detection: Results of a Prospective Multicenter Clinical Trial. <i>Journal of Urology</i> , 2003, 170, 1787-1791.	0.4	109
85	Use of nuclear morphometry, gleason histologic scoring, clinical stage, and age to predict disease-free survival among patients with prostate cancer. <i>Cancer</i> , 1992, 70, 161-168.	4.1	107
86	Proenzyme psa for the early detection of prostate cancer in the 2.5-4.0 ng/ml total psa range: preliminary analysis. <i>Urology</i> , 2003, 61, 274-276.	1.0	106
87	Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. <i>Cancer</i> , 2006, 107, 1265-1272.	4.1	102
88	Comparison of clinical staging algorithms and $^{111}\text{In}$ -capromab pentetide immunoscintigraphy in the prediction of lymph node involvement in high risk prostate carcinoma patients. <i>Cancer</i> , 1999, 85, 1586-1592.	4.1	101
89	Monoclonal antibody to prostate cancer nuclear matrix protein (PRO:4-216) recognizes nucleophosmin/B23. , 1999, 39, 298-304.		100
90	THE USE OF PERCENT FREE PROSTATE SPECIFIC ANTIGEN FOR STAGING CLINICALLY LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 1998, 159, 1238-1242.	0.4	99

#	ARTICLE	IF	CITATIONS
91	[-2]Proenzyme Prostate Specific Antigen for Prostate Cancer Detection: A National Cancer Institute Early Detection Research Network Validation Study. <i>Journal of Urology</i> , 2008, 180, 539-543.	0.4	98
92	Multiparametric magnetic resonance imaging findings in men with low-risk prostate cancer followed using active surveillance. <i>BJU International</i> , 2013, 111, 1037-1045.	2.5	95
93	Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5,895 prostate cancer patients. <i>Prostate</i> , 2009, 69, 1195-1205.	2.3	93
94	OBESITY AND CAPSULAR INCISION AT THE TIME OF OPEN RETROPUBIC RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2005, 174, 1798-1801.	0.4	91
95	Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. <i>Therapeutic Advances in Urology</i> , 2015, 7, 378-387.	2.0	91
96	Percentage of free prostate-specific antigen in sera predicts aggressiveness of prostate cancer a decade before diagnosis. <i>Urology</i> , 1997, 49, 379-384.	1.0	90
97	Gleason Score 7 Prostate Cancer on Needle Biopsy: Is the Prognostic Difference in Gleason Scores 4+3 and 3+4 Independent of the Number of Involved Cores?. <i>Journal of Urology</i> , 2002, 167, 2440-2442.	0.4	90
98	An algorithm combining age, total prostate-specific antigen (PSA), and percent free PSA to predict prostate cancer: results on 4298 cases. <i>Urology</i> , 1998, 52, 455-461.	1.0	89
99	Pathological Outcomes in Men with Low Risk and Very Low Risk Prostate Cancer: Implications on the Practice of Active Surveillance. <i>Journal of Urology</i> , 2013, 190, 1218-1223.	0.4	89
100	Small High Grade Adenocarcinoma of the Prostate in Radical Prostatectomy Specimens Performed for Nonpalpable Disease: Pathogenetic and Clinical Implications. <i>Journal of Urology</i> , 1994, 151, 1587-1592.	0.4	87
101	Clinical utility of indium 111-capromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. <i>Cancer</i> , 2002, 94, 987-996.	4.1	86
102	Prediction of pathological stage based on clinical stage, serum prostate-specific antigen, and biopsy Gleason score: Partin Tables in the contemporary era. <i>BJU International</i> , 2017, 119, 676-683.	2.5	86
103	Prostate Specific Membrane Antigen Targeted <sup>18</sup> F-DCFPyL Positron Emission Tomography/Computerized Tomography for the Preoperative Staging of High Risk Prostate Cancer: Results of a Prospective, Phase II, Single Center Study. <i>Journal of Urology</i> , 2018, 199, 126-132.	0.4	86
104	DISEASE PROGRESSION FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH GLEASON SCORE 7 TUMOR. <i>Journal of Urology</i> , 1998, 160, 97-101.	0.4	84
105	Tumor Grade at Margins of Resection in Radical Prostatectomy Specimens Is an Independent Predictor of Prognosis. <i>Urology</i> , 2010, 76, 1206-1209.	1.0	83
106	PREDICTION OF POST-RADICAL PROSTATECTOMY PATHOLOGICAL OUTCOME FOR STAGE T1c PROSTATE CANCER WITH PERCENT FREE PROSTATE SPECIFIC ANTIGEN: A PROSPECTIVE MULTICENTER CLINICAL TRIAL. <i>Journal of Urology</i> , 1999, 162, 1346-1351.	0.4	82
107	Prognostic Value of Preoperative Serum Cell-Free Circulating DNA in Men with Prostate Cancer Undergoing Radical Prostatectomy. <i>Clinical Cancer Research</i> , 2007, 13, 5361-5367.	7.0	82
108	Impact of surgical margin status on prostate cancer-specific mortality. <i>BJU International</i> , 2012, 110, 1684-1689.	2.5	82



#	ARTICLE	IF	CITATIONS
109	PSA markers in prostate cancer detection. <i>Urologic Clinics of North America</i> , 2003, 30, 677-686.	1.8	81
110	The influence of finasteride on the volume of the peripheral and periurethral zones of the prostate in men with benign prostatic hyperplasia. <i>Prostate</i> , 1993, 22, 39-42.	2.3	80
111	Molecular and cellular changes associated with the acquisition of metastatic ability by prostatic cancer cells. <i>Prostate</i> , 1994, 25, 249-265.	2.3	79
112	Extended Followup of the Influence of Wide Excision of the Neurovascular Bundle(s) on Prognosis in Men with Clinically Localized Prostate Cancer and Extensive Capsular Perforation. <i>Journal of Urology</i> , 1996, 156, 454-458.	0.4	79
113	Evaluation of Prostate Specific Antigen for Early Detection of Prostate Cancer in Men With a Total Prostate Specific Antigen Range of 4.0 to 10.0 Ng/ML. <i>Journal of Urology</i> , 2003, 170, 723-726.	0.4	79
114	Genetically engineered neural networks for predicting prostate cancer progression after radical prostatectomy. <i>Urology</i> , 1999, 54, 791-795.	1.0	78
115	Prognostic Significance of Gleason Score Discrepancies between Needle Biopsy and Radical Prostatectomy. <i>European Urology</i> , 2008, 53, 767-776.	1.9	77
116	Prediction of Mortality After Radical Prostatectomy by Charlson Comorbidity Index. <i>Urology</i> , 2010, 76, 553-557.	1.0	77
117	Contemporary identification of patients at high risk of early prostate cancer recurrence after radical retropubic prostatectomy. <i>Urology</i> , 2001, 57, 1033-1037.	1.0	76
118	Positive proximal (bladder neck) margin at radical prostatectomy confers greater risk of biochemical progression. <i>Urology</i> , 2004, 64, 551-555.	1.0	76
119	Probability of biochemical recurrence by analysis of pathologic stage, gleason score, and margin status for localized prostate cancer. <i>Urology</i> , 2003, 62, 866-871.	1.0	75
120	Risk score predicts high-grade prostate cancer in DNA-methylation positive, histopathologically negative biopsies. <i>Prostate</i> , 2016, 76, 1078-1087.	2.3	74
121	Prostate Tissue Composition and Response to Finasteride in Men With Symptomatic Benign Prostatic Hyperplasia. <i>Journal of Urology</i> , 1997, 157, 2171-2178.	0.4	71
122	Does capsular incision at radical retropubic prostatectomy affect disease-free survival in otherwise organ-confined prostate cancer?. <i>Urology</i> , 2001, 58, 746-751.	1.0	71
123	Can Prostate Specific Antigen Derivatives and Pathological Parameters Predict Significant Change in Expectant Management Criteria for Prostate Cancer?. <i>Journal of Urology</i> , 2003, 170, 2274-2278.	0.4	71
124	Extent of Extraprostatic Extension Independently Influences Biochemical Recurrence-free Survival: Evidence for Further pT3 Subclassification. <i>Urology</i> , 2015, 85, 161-164.	1.0	71
125	Prostate Health Index improves multivariable risk prediction of aggressive prostate cancer. <i>BJU International</i> , 2017, 120, 61-68.	2.5	71
126	A Contemporary Analysis of Outcomes of Adenocarcinoma of the Prostate With Seminal Vesicle Invasion (pT3b) After Radical Prostatectomy. <i>Journal of Urology</i> , 2011, 185, 1691-1697.	0.4	70



#	ARTICLE	IF	CITATIONS
127	Combining Prostate Health Index density, magnetic resonance imaging and prior negative biopsy status to improve the detection of clinically significant prostate cancer. <i>BJU International</i> , 2018, 121, 619-626.	2.5	70
128	BIOLOGICAL AGGRESSIVENESS OF HEREDITARY PROSTATE CANCER: LONG-TERM EVALUATION FOLLOWING RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 1998, 160, 660-663.	0.4	69
129	A neural network predicts progression for men with Gleason score 3+4 versus 4+3 tumors after radical prostatectomy. <i>Urology</i> , 2000, 56, 994-999.	1.0	69
130	Prostate Health Index density improves detection of clinically significant prostate cancer. <i>BJU International</i> , 2017, 120, 793-798.	2.5	69
131	CpG Island Hypermethylation Profile in the Serum of Men With Clinically Localized and Hormone Refractory Metastatic Prostate Cancer. <i>Journal of Urology</i> , 2008, 179, 529-535.	0.4	68
132	THE PROSTATIC SPECIFIC ANTIGEN ERA IS ALIVE AND WELL: PROSTATIC SPECIFIC ANTIGEN AND BIOCHEMICAL PROGRESSION FOLLOWING RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 2005, 174, 1276-1281.	0.4	67
133	Evaluation of Smooth Muscle and Collagen Subtypes in Normal Newborns and Those With Bladder Exstrophy. <i>Journal of Urology</i> , 1996, 156, 2034-2036.	0.4	66
134	Detection of Prostate Cancer Using Serum Proteomics Pattern in a Histologically Confirmed Population. <i>Journal of Urology</i> , 2004, 171, 1782-1787.	0.4	65
135	Initial Experience Performing In-office Ultrasound-guided Transperineal Prostate Biopsy Under Local Anesthesia Using the PrecisionPoint Transperineal Access System. <i>Urology</i> , 2018, 115, 8-13.	1.0	65
136	Artificial neural network model for the assessment of lymph node spread in patients with clinically localized prostate cancer. <i>Urology</i> , 2001, 57, 481-485.	1.0	64
137	T-Cell Infiltration and Adaptive Treg Resistance in Response to Androgen Deprivation With or Without Vaccination in Localized Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 3182-3192.	7.0	64
138	Immunohistochemical staining of prostate cancer with monoclonal antibodies to the precursor of prostate-specific antigen. <i>Urology</i> , 2003, 62, 177-181.	1.0	63
139	Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma. <i>Cancer</i> , 2001, 91, 1661-1666.	4.1	62
140	Complexed prostate-specific antigen for early detection of prostate cancer in men with serum prostate-specific antigen levels of 2 to 4 nanograms per milliliter. <i>Urology</i> , 2002, 60, 31-35.	1.0	62
141	Natural history of disease progression in patients who fail to achieve an undetectable prostate-specific antigen level after undergoing radical prostatectomy. <i>Cancer</i> , 2004, 101, 2549-2556.	4.1	61
142	Association of Prostate Cancer Risk Variants with Clinicopathologic Characteristics of the Disease. <i>Clinical Cancer Research</i> , 2008, 14, 5819-5824.	7.0	61
143	The Natural History of Men Treated With Deferred Androgen Deprivation Therapy in Whom Metastatic Prostate Cancer Developed Following Radical Prostatectomy. <i>Journal of Urology</i> , 2008, 179, 156-162.	0.4	60
144	INFLUENCE OF FINASTERIDE ON FREE AND TOTAL SERUM PROSTATE SPECIFIC ANTIGEN LEVELS IN MEN WITH BENIGN PROSTATIC HYPERPLASIA. <i>Journal of Urology</i> , 1998, 159, 449-453.	0.4	59

#	ARTICLE	IF	CITATIONS
145	Age, prostate-specific antigen, and digital rectal examination as determinants of the probability of having prostate cancer. <i>Urology</i> , 2001, 57, 1100-1104.	1.0	59
146	The role of free/total prostate-specific antigen ratio in the prediction of final pathologic stage for men with clinically localized prostate cancer. <i>Urology</i> , 1996, 48, 51-54.	1.0	57
147	Bioimpedance: Novel use of a minimally invasive technique for cancer localization in the intact prostate. , 1999, 39, 213-218.		57
148	Phase II, Randomized, Placebo-Controlled Trial of Neoadjuvant Celecoxib in Men With Clinically Localized Prostate Cancer: Evaluation of Drug-Specific Biomarkers. <i>Journal of Clinical Oncology</i> , 2009, 27, 4986-4993.	1.6	57
149	Prostate-Specific Antigen Measurements in Serum and Tissue Are Associated with Treatment Necessity among Men Enrolled in Expectant Management for Prostate Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 7316-7321.	7.0	57
150	Increased gene copy number of ERG on chromosome 21 but not TMPRSS2-ERG fusion predicts outcome in prostatic adenocarcinomas. <i>Modern Pathology</i> , 2011, 24, 1511-1520.	5.5	57
151	ABILITY OF THE 1992 AND 1997 AMERICAN JOINT COMMITTEE ON CANCER STAGING SYSTEMS FOR PROSTATE CANCER TO PREDICT PROGRESSION-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY FOR STAGE T2 DISEASE. <i>Journal of Urology</i> , 2000, 164, 89-92.	0.4	56
152	Prostate Specific Antigen Predicts the Long-Term Risk of Prostate Enlargement: Results from the Baltimore Longitudinal Study of Aging. <i>Journal of Urology</i> , 2002, 167, 2484-2487.	0.4	56
153	Racial Disparities in Oncologic Outcomes After Radical Prostatectomy: Long-term Follow-up. <i>Urology</i> , 2014, 84, 1434-1441.	1.0	56
154	DIGITAL RECTAL EXAMINATION AND IMAGING STUDIES ARE UNNECESSARY IN MEN WITH UNDETECTABLE PROSTATE SPECIFIC ANTIGEN FOLLOWING RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 1999, 162, 1337-1340.	0.4	55
155	Long-term Survival After Radical Prostatectomy for Men With High Gleason Sum in Pathologic Specimen. <i>Urology</i> , 2010, 76, 715-721.	1.0	55
156	Fifth-Generation Digital Immunoassay for Prostate-Specific Antigen by Single Molecule Array Technology. <i>Clinical Chemistry</i> , 2011, 57, 1712-1721.	3.2	55
157	Validation of a biopsy-based pathologic algorithm for predicting lymph node metastases in patients with clinically localized prostate carcinoma. <i>Cancer</i> , 2002, 95, 1016-1021.	4.1	54
158	Quantitative nuclear grade (QNG): A new image analysis-based biomarker of clinically relevant nuclear structure alterations. <i>Journal of Cellular Biochemistry</i> , 2000, 79, 151-157.	2.6	53
159	Contemporary use of complexed PSA and calculated percent free PSA for early detection of prostate cancer: impact of changing disease demographics. <i>Urology</i> , 2001, 57, 1105-1111.	1.0	53
160	Pathologic findings in clinical stage A2 prostate cancer. Relation of tumor volume, grade, and location to pathologic stage. <i>Cancer</i> , 1990, 65, 1021-1027.	4.1	52
161	Influence of biopsy perineural invasion on long-term biochemical disease-free survival after radical prostatectomy. <i>Urology</i> , 2002, 59, 85-90.	1.0	52
162	Prospective Multicenter Evaluation of the Beckman Coulter Prostate Health Index Using WHO Calibration. <i>Journal of Urology</i> , 2013, 189, 1702-1706.	0.4	51

#	ARTICLE	IF	CITATIONS
163	A Phase I Study to Assess the Safety and Cancer-Homing Ability of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cells in Men with Localized Prostate Cancer. <i>Stem Cells Translational Medicine</i> , 2019, 8, 441-449.	3.3	50
164	Comparison of serum PSMA, PSA levels with results of cytogen-356 ProstaScint® scanning in prostatic cancer patients. , 1997, 33, 281-285.		49
165	Clinical utility of proPSA and Æbenignâ€•PSA when percent free PSA is less than 15%. <i>Urology</i> , 2004, 64, 1160-1164.	1.0	49
166	Family history facilitates the early diagnosis of prostate carcinoma. , 1997, 80, 1871-1874.		48
167	Percentage of free PSA in black versus white men for detection and staging of prostate cancer: a prospective multicenter clinical trial. <i>Urology</i> , 2000, 55, 372-376.	1.0	47
168	Cumulative effect of five genetic variants on prostate cancer risk in multiple study populations. <i>Prostate</i> , 2008, 68, 1257-1262.	2.3	47
169	Validation of the Partin Nomogram for Prostate Cancer in a National Sample. <i>Journal of Urology</i> , 2010, 183, 105-111.	0.4	47
170	ProPSA and Diagnostic Biopsy Tissue DNA Content Combination Improves Accuracy to Predict Need for Prostate Cancer Treatment Among Men Enrolled in an Active Surveillance Program. <i>Urology</i> , 2011, 77, 763.e1-763.e6.	1.0	47
171	Obesity and Long-Term Survival after Radical Prostatectomy. <i>Journal of Urology</i> , 2014, 192, 1100-1104.	0.4	47
172	The Relationship Between the Extent of Extraprostatic Extension and Survival Following Radical Prostatectomy. <i>European Urology</i> , 2015, 67, 342-346.	1.9	47
173	A Quantitative Histological Analysis of the Dilated Ureter of Childhood. <i>Journal of Urology</i> , 1992, 148, 1482-1486.	0.4	46
174	Ability to predict biochemical progression using gleason score and a computer-generated quantitative nuclear grade derived from cancer cell nuclei. <i>Urology</i> , 1996, 48, 685-691.	1.0	46
175	Prostate cancer in native Japanese and Japanese-American men: Effects of dietary differences on prostatic tissue. <i>Urology</i> , 2004, 64, 765-771.	1.0	46
176	Adjuvant Weekly Docetaxel for Patients With High Risk Prostate Cancer After Radical Prostatectomy: A Multi-Institutional Pilot Study. <i>Journal of Urology</i> , 2007, 177, 1777-1781.	0.4	45
177	Original Articles: Prostate Cancer: Deoxyribonucleic Acid Ploidy Analysis as a Predictor of Recurrence Following Radical Prostatectomy for Stage T2 Disease. <i>Journal of Urology</i> , 1995, 153, 1015-1019.	0.4	44
178	New Prostate Cancer Grading System Predicts Long-term Survival Following Surgery for Gleason Score 8â€“10 Prostate Cancer. <i>European Urology</i> , 2017, 71, 907-912.	1.9	44
179	Importance of Reporting the Gleason Score at the Positive Surgical Margin Site: Analysis of 4,082 Consecutive Radical Prostatectomy Cases. <i>Journal of Urology</i> , 2016, 195, 337-342.	0.4	43
180	Evaluation of artificial neural networks for the prediction of pathologic stage in prostate carcinoma. <i>Cancer</i> , 2001, 91, 1661-1666.	4.1	43

#	ARTICLE	IF	CITATIONS
181	CORRELATION OF SERUM PROSTATE SPECIFIC ANTIGEN AND QUANTITATIVE IMMUNOHISTOCHEMISTRY. Journal of Urology, 2000, 163, 1739-1742.	0.4	42
182	The Evolving Role of Docetaxel in the Management of Androgen Independent Prostate Cancer. Journal of Urology, 2003, 170, 1709-1716.	0.4	42
183	The Relationship of Prostate Specific Antigen Levels and Residual Tumor Volume in Stage a Prostate Cancer. Journal of Urology, 1990, 144, 1167-1170.	0.4	41
184	Association between sequence variants at 17q12 and 17q24.3 and prostate cancer risk in European and African Americans. Prostate, 2008, 68, 691-697.	2.3	41
185	Modeling grade progression in an active surveillance study. Statistics in Medicine, 2014, 33, 930-939.	1.6	41
186	Analytical Validation of Androgen Receptor Splice Variant 7 Detection in a Clinical Laboratory Improvement Amendments (CLIA) Laboratory Setting. Journal of Molecular Diagnostics, 2017, 19, 115-125.	2.8	41
187	Preoperative characteristics of highâ€Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy. BJU International, 2012, 110, 1122-1128.	2.5	39
188	Urinary Biomarkers for Prostate Cancer. Urologic Clinics of North America, 2016, 43, 17-38.	1.8	39
189	SPINK1 Defines a Molecular Subtype of Prostate Cancer in Men with More Rapid Progression in an at Risk, Natural History Radical Prostatectomy Cohort. Journal of Urology, 2016, 196, 1436-1444.	0.4	38
190	Serum Prostate Specific Antigen Levels after Transurethral Resection of Prostate: A Longitudinal Characterization in Men with Benign Prostatic Hyperplasia. Journal of Urology, 1996, 156, 1035-1039.	0.4	37
191	Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer. Urology, 1997, 50, 715-721.	1.0	37
192	MINILAPAROTOMY RADICAL RETROPUBIC PROSTATECTOMY. Journal of Urology, 1998, 160, 2440-2445.	0.4	37
193	Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. Cancer, 2000, 89, 2577-2586.	4.1	37
194	A neurocomputational model for prostate carcinoma detection. Cancer, 2003, 98, 1849-1854.	4.1	37
195	Percent Free Prostate Specific Antigen in the Total Prostate Specific Antigen 2 to 4 ng./ml. Range Does Not Substantially Increase the Number of Biopsies Needed to Detect Clinically Significant Prostate Cancer Compared to the 4 to 10 ng./ml. Range. Journal of Urology, 2002, 168, 504-508.	0.4	36
196	Prediction of patientâ€specific risk and percentile cohort risk of pathological stage outcome using continuous prostateâ€specific antigen measurement, clinical stage and biopsy Gleason score. BJU International, 2011, 107, 1562-1569.	2.5	36
197	Evaluating the impact of length of time from diagnosis to surgery in patients with unfavourable intermediateâ€risk to veryâ€highâ€risk clinically localised prostate cancer. BJU International, 2019, 124, 268-274.	2.5	36
198	Adenocarcinoma of the prostate in men younger than 40 years of age: diagnosis and treatment with emphasis on radical prostatectomy findings. Urology, 1999, 53, 1179-1183.	1.0	35

#	ARTICLE	IF	CITATIONS
199	PSA Levels and the Probability of Prostate Cancer on Biopsy. <i>European Urology Supplements</i> , 2002, 1, 21-27.	0.1	35
200	Prostate-specific antigen doubling time in the identification of patients at risk for progression after treatment and biochemical recurrence for prostate cancer. <i>Urology</i> , 2003, 62, 2-8.	1.0	35
201	Impact of age on total and complexed prostate-specific antigen cutoffs in a contemporary referral series of men with prostate cancer. <i>Urology</i> , 2002, 60, 47-52.	1.0	34
202	Management of High-Risk Populations with Locally Advanced Prostate Cancer. <i>Oncologist</i> , 2003, 8, 259-269.	3.7	34
203	Black Race Does Not Independently Predict Adverse Outcome Following Radical Retropubic Prostatectomy at a Tertiary Referral Center. <i>Journal of Urology</i> , 2006, 176, 515-519.	0.4	34
204	Relationship between primary Gleason pattern on needle biopsy and clinicopathologic outcomes among men with Gleason score 7 adenocarcinoma of the prostate. <i>Urology</i> , 2006, 67, 115-119.	1.0	34
205	Adjuvant radiation with androgen-deprivation therapy for men with lymph node metastases after radical prostatectomy: identifying men who benefit. <i>BJU International</i> , 2019, 123, 252-260.	2.5	34
206	Comparison of Logistic Regression and Neural Net Modeling for Prediction of Prostate Cancer Pathologic Stage. <i>Clinical Chemistry</i> , 2002, 48, 1828-1834.	3.2	33
207	DIFFERENTIAL NUCLEAR MATRIX PROTEIN EXPRESSION IN PROSTATE CANCERS: CORRELATION WITH PATHOLOGIC STAGE. <i>Journal of Urology</i> , 1998, 159, 1354-1358.	0.4	31
208	Prediction of prostate carcinoma stage by quantitative biopsy pathology. <i>Cancer</i> , 2001, 91, 2322-2328.	4.1	31
209	Long-Term assessment of prostate cancer progression free survival: Evaluation of pathological parameters, nuclear shape and molecular biomarkers of pathogenesis. <i>Prostate</i> , 2008, 68, 1806-1815.	2.3	31
210	ISOLATED LOCAL RECURRENCE IS RARE AFTER RADICAL PROSTATECTOMY IN MEN WITH GLEASON 7 PROSTATE CANCER AND POSITIVE SURGICAL MARGINS: THERAPEUTIC IMPLICATIONS. <i>Journal of Urology</i> , 2001, 165, 864-866.	0.4	30
211	Prostate Specific Antigen Versus Prostate Specific Antigen Density as a Prognosticator of Pathological Characteristics and Biochemical Recurrence Following Radical Prostatectomy. <i>Journal of Urology</i> , 2008, 179, 1780-1784.	0.4	30
212	Multicenter comparison of the diagnostic performance of free prostate-specific antigen. <i>Urology</i> , 1996, 48, 45-50.	1.0	29
213	Incidental non-Hodgkin's lymphoma in patients with localized prostate cancer. <i>Urology</i> , 1999, 53, 175-179.	1.0	29
214	Substratification of stage T1C prostate cancer based on the probability of biochemical recurrence. <i>Urology</i> , 2002, 60, 1034-1039.	1.0	29
215	Quantitative biopsy pathology for the prediction of pathologically organ-confined prostate carcinoma. <i>Cancer</i> , 2003, 97, 969-978.	4.1	29
216	Serum acid phosphatase level and biochemical recurrence following radical prostatectomy for men with clinically localized prostate cancer. <i>Urology</i> , 2001, 57, 707-711.	1.0	28

#	ARTICLE	IF	CITATIONS
217	Pathological Outcomes and Biochemical Progression in Men With T1c Prostate Cancer Undergoing Radical Prostatectomy With Prostate Specific Antigen 2.6 to 4.0 vs 4.1 to 6.0 ng/ml. <i>Journal of Urology</i> , 2006, 176, 554-558.	0.4	28
218	THE USE OF PROSTATE-SPECIFIC ANTIGEN AND FREE/TOTAL PROSTATE-SPECIFIC ANTIGEN IN THE DIAGNOSIS OF LOCALIZED PROSTATE CANCER. <i>Urologic Clinics of North America</i> , 1996, 23, 531-540.	1.8	27
219	Short-term stability of the molecular forms of prostate-specific antigen and effect on percent complexed prostate-specific antigen and percent free prostate-specific antigen. <i>Urology</i> , 2002, 60, 24-30.	1.0	27
220	Prediction of Pathological Stage in Patients with Clinical Stage T1c Prostate Cancer: The New Challenge. <i>Journal of Urology</i> , 2002, 168, 100-104.	0.4	27
221	Gleason score 7 prostate cancer on needle biopsy: is the prognostic difference in Gleason scores 4 + 3 and 3 + 4 independent of the number of involved cores?. <i>Journal of Urology</i> , 2002, 167, 2440-2.	0.4	27
222	Automated image analysis system for detecting boundaries of live prostate cancer cells. , 1998, 31, 287-294.		26
223	PSA Doubling Time and Absolute PSA Predict Metastasis-free Survival in Men With Biochemically Recurrent Prostate Cancer After Radical Prostatectomy. <i>Clinical Genitourinary Cancer</i> , 2019, 17, 470-475.e1.	1.9	26
224	Re: The Use of Prostate Specific Antigen, Clinical Stage and Gleason Score to Predict Pathological Stage in Men with Localized Prostate Cancer, by A. W. Partin, J. Yoo, H. B. Carter, J. D. Pearson, D. W. Chan, J. I. Epstein and P. C. Walsh, <i>J. Urol.</i> , 150: 110â€“115, 1993. <i>Journal of Urology</i> , 1994, 152, 172-173.	0.4	25
225	Probability of prostate cancer detection based on results of a multicenter study using the AxSYM free PSA and total PSA assays. <i>Urology</i> , 2000, 55, 909-914.	1.0	25
226	COMPARISON OF PREDICTIVE ACCURACY FOR PATHOLOGICALLY ORGAN CONFINED CLINICAL STAGE T1c PROSTATE CANCER USING HUMAN GLANDULAR KALLIKREIN 2 AND PROSTATE SPECIFIC ANTIGEN COMBINED WITH CLINICAL STAGE AND GLEASON GRADE. <i>Journal of Urology</i> , 2005, 173, 752-756.	0.4	25
227	Using nuclear morphometry to predict the need for treatment among men with low grade, low stage prostate cancer enrolled in a program of expectant management with curative intent. <i>Prostate</i> , 2008, 68, 183-189.	2.3	25
228	Indications for intervention during active surveillance of prostate cancer: a comparison of the <sc>J</sc>ohns <sc>H</sc>opkins and <sc>P</sc>rostate <sc>C</sc>ancer <sc>R</sc>esearch <sc>I</sc>nternational <sc>A</sc>ctive <sc>S</sc>urveillance (<sc>PRIAS</sc>) protocols. <i>BJU International</i> , 2015, 115, 216-222.	2.5	25
229	Radical prostatectomy as treatment for prostate-specific antigen-detected stage T1c prostate cancer. <i>World Journal of Urology</i> , 1997, 15, 373-377.	2.2	24
230	Prostate-Specific Antigen: Update 2006. <i>Urology</i> , 2006, 67, 458-460.	1.0	24
231	Identification of men with the highest risk of early disease recurrence after radical prostatectomy. <i>Prostate</i> , 2014, 74, 628-636.	2.3	24
232	Standardization of Two Immunoassays for Human Glandular Kallikrein 2. <i>Clinical Chemistry</i> , 2003, 49, 601-610.	3.2	23
233	Significant variations in nuclear structure occur between and within Gleason grading patterns 3, 4, and 5 determined by digital image analysis. <i>Prostate</i> , 2007, 67, 1202-1210.	2.3	23
234	Utility of Risk Models in Decision Making After Radical Prostatectomy: Lessons from a Natural History Cohort of Intermediate- and High-Risk Men. <i>European Urology</i> , 2016, 69, 496-504.	1.9	23



#	ARTICLE	IF	CITATIONS
235	Obesity and prostate enlargement in men with localized prostate cancer. <i>BJU International</i> , 2011, 108, 1750-1755.	2.5	22
236	Evolution of the clinical presentation of men undergoing radical prostatectomy for high-risk prostate cancer. <i>BJU International</i> , 2012, 109, 988-993.	2.5	22
237	Effect of Pharmacologic Prophylaxis on Venous Thromboembolism After Radical Prostatectomy: The PREVENTER Randomized Clinical Trial. <i>European Urology</i> , 2020, 78, 360-368.	1.9	22
238	Complexed prostate-specific antigen as a staging tool: results based on a multicenter prospective evaluation of complexed prostate-specific antigen in cancer diagnosis. <i>Urology</i> , 2002, 60, 10-17.	1.0	21
239	Prognostic value of Her2/neu and DNA index for progression, metastasis and prostate cancer-specific death in men with long-term follow-up after radical prostatectomy. <i>International Journal of Cancer</i> , 2008, 123, 2636-2643.	5.1	21
240	Advances in the selection of patients with prostate cancer for active surveillance. <i>Nature Reviews Urology</i> , 2021, 18, 197-208.	3.8	21
241	Feasibility of integrating canine olfaction with chemical and microbial profiling of urine to detect lethal prostate cancer. <i>PLoS ONE</i> , 2021, 16, e0245530.	2.5	21
242	Transperineal Prostate Biopsy Improves the Detection of Clinically Significant Prostate Cancer among Men on Active Surveillance. <i>Journal of Urology</i> , 2021, 205, 1069-1074.	0.4	21
243	Management of patients with an increasing prostate-specific antigen after radical prostatectomy. <i>Current Urology Reports</i> , 2004, 5, 179-187.	2.2	20
244	Radical Prostatectomy Outcome in Men 65 Years Old or Older With Low Risk Prostate Cancer. <i>Journal of Urology</i> , 2012, 187, 1620-1625.	0.4	20
245	Outcomes of men with an elevated prostate-specific antigen (PSA) level as their sole preoperative intermediate- or high-risk feature. <i>BJU International</i> , 2014, 114, E120-E129.	2.5	20
246	Pharmacodynamic and pharmacokinetic neoadjuvant study of hedgehog pathway inhibitor Sonidegib (LDE-225) in men with high-risk localized prostate cancer undergoing prostatectomy. <i>Oncotarget</i> , 2017, 8, 104182-104192.	1.8	20
247	INDICATORS OF PATHOLOGIC STAGE OF PROSTATE CANCER AND THEIR USE IN CLINICAL PRACTICE. <i>Urologic Clinics of North America</i> , 2001, 28, 443-458.	1.8	19
248	Do Racial Differences in Prostate Size Explain Higher Serum Prostate-Specific Antigen Concentrations Among Black Men?. <i>Urology</i> , 2007, 69, 1138-1142.	1.0	19
249	Utility of multiparametric magnetic resonance imaging in the risk stratification of men with Grade Group 1 prostate cancer on active surveillance. <i>BJU International</i> , 2020, 125, 861-866.	2.5	19
250	ELEVATED PROSTATE-SPECIFIC ANTIGEN, ABNORMAL PROSTATE EVALUATION ON DIGITAL RECTAL EXAMINATION, AND TRANSRECTAL ULTRASOUND AND PROSTATE BIOPSY. <i>Urologic Clinics of North America</i> , 1998, 25, 581-589.	1.8	18
251	Exploratory data analysis groupware for qualitative and quantitative electrophoretic gel analysis over the Internet-WebGel. <i>Electrophoresis</i> , 1999, 20, 3492-3507.	2.4	18
252	Body Mass Index and Prostate Specific Antigen as Predictors of Adverse Pathology and Biochemical Recurrence After Prostatectomy. <i>Journal of Urology</i> , 2009, 182, 491-498.	0.4	18



#	ARTICLE	IF	CITATIONS
253	Prostate Health Index (PHI) Predicts High-stage Pathology in African American Men. <i>Urology</i> , 2016, 90, 136-140.	1.0	18
254	Review of the literature: PCA3 for prostate cancer risk assessment and prognostication. <i>Reviews in Urology</i> , 2011, 13, e191-5.	0.9	18
255	INFLUENCE OF SEXTANT PROSTATE NEEDLE BIOPSY OR SURGERY ON THE DETECTION AND HARVEST OF INTACT CIRCULATING PROSTATE CANCER CELLS. <i>Journal of Urology</i> , 1999, 162, 749-752.	0.4	17
256	Prediction of locoregional extension and metastatic disease in prostate cancer: a review. <i>World Journal of Urology</i> , 2000, 18, 165-172.	2.2	17
257	Mass Spectroscopy as a Discovery Tool for Identifying Serum Markers for Prostate Cancer. <i>Clinical Chemistry</i> , 2001, 47, 1924-1926.	3.2	17
258	Clinical evaluation of a novel method for the measurement of prostate-specific antigen, AccuPSA <sup>TM</sup> , as a predictor of 5-year biochemical recurrence-free survival after radical prostatectomy: results of a pilot study. <i>BJU International</i> , 2012, 109, 1770-1775.	2.5	17
259	Serum prostate-specific antigen (PSA) concentration is positively associated with rate of disease reclassification on subsequent active surveillance prostate biopsy in men with low PSA density. <i>BJU International</i> , 2014, 113, 561-567.	2.5	17
260	Implementation of a Surgeon-Level Comparative Quality Performance Review to Improve Positive Surgical Margin Rates during Radical Prostatectomy. <i>Journal of Urology</i> , 2017, 197, 1245-1250.	0.4	16
261	The importance of pelvic lymph node dissection in men with clinically localized prostate cancer. <i>Reviews in Urology</i> , 2006, 8, 112-9.	0.9	16
262	Applying complexed prostate-specific antigen to clinical practice. <i>Urology</i> , 2004, 63, 815-818.	1.0	15
263	DNA Ploidy as Surrogate for Biopsy Gleason Score for Preoperative Organ Versus Nonorgan-confined Prostate Cancer Prediction. <i>Urology</i> , 2009, 73, 1092-1097.	1.0	15
264	Subtyping the Risk of Intermediate Risk Prostate Cancer for Active Surveillance Based on Adverse Pathology at Radical Prostatectomy. <i>Journal of Urology</i> , 2018, 200, 1068-1074.	0.4	15
265	Prostate-specific antigen as a marker of disease activity in prostate cancer. <i>Oncology</i> , 2002, 16, 1024-38, 1042; discussion 1042, 1047-8, 1051.	0.5	15
266	Surgical margin status after radical retropubic prostatectomy. <i>BJU International</i> , 2005, 95, 281-284.	2.5	14
267	Do Ultrasensitive Prostate Specific Antigen Measurements Have a Role in Predicting Long-Term Biochemical Recurrence-Free Survival in Men after Radical Prostatectomy?. <i>Journal of Urology</i> , 2016, 195, 330-336.	0.4	14
268	Nuclear morphometry predicts disease-free interval for clinically localized adenocarcinoma of the prostate treated with definitive radiation therapy. <i>International Journal of Cancer</i> , 1999, 84, 594-597.	5.1	13
269	The impact of preoperative erectile dysfunction on survival after radical prostatectomy. <i>BJU International</i> , 2010, 106, 1612-1617.	2.5	13
270	Cyr61 is regulated by cAMP-dependent protein kinase with serum levels correlating with prostate cancer aggressiveness. <i>Prostate</i> , 2012, 72, 966-976.	2.3	13

#	ARTICLE	IF	CITATIONS
271	Adenocarcinoma of the Prostate with Gleason Score 9-10 on Core Biopsy: Correlation with Findings at Radical Prostatectomy and Prognosis. <i>Journal of Urology</i> , 2013, 190, 2068-2073.	0.4	13
272	Pathological analysis of the prostatic anterior fat pad at radical prostatectomy: insights from a prospective series. <i>BJU International</i> , 2017, 119, 444-448.	2.5	13
273	Clinical Validation of the 2005 ISUP Gleason Grading System in a Cohort of Intermediate and High Risk Men Undergoing Radical Prostatectomy. <i>PLoS ONE</i> , 2016, 11, e0146189.	2.5	13
274	Diagnosis of localized prostate cancer: 10 years of progress. <i>Current Opinion in Urology</i> , 2000, 10, 319-327.	1.8	12
275	Complexed prostate-specific antigen as a staging tool for prostate cancer: a prospective study in 420 men. <i>Urology</i> , 2002, 60, 18-23.	1.0	12
276	Neoadjuvant randomized trial of degarelix (Deg) ± cyclophosphamide/GVAX (Cy/GVAX) in men with high-risk prostate cancer (PCa) undergoing radical prostatectomy (RP).. <i>Journal of Clinical Oncology</i> , 2017, 35, 5077-5077.	1.6	12
277	Role of laparoscopy in the diagnosis and treatment of prostate cancer. , 1996, 12, 139-144.		11
278	Report on Prostate Cancer Tumor Marker Workshop 1999. <i>Cancer</i> , 2000, 88, 955-963.	4.1	11
279	Can volume measurement of the prostate enhance the performance of complexed prostate-specific antigen?. <i>Urology</i> , 2002, 60, 36-41.	1.0	11
280	Volume indexes of total, free, and complexed prostate-specific antigen enhance prediction of extraprostatic disease extension in men with nonpalpable prostate cancer. <i>Urology</i> , 2003, 62, 1058-1062.	1.0	11
281	An Approach Using PSA Levels of 1.5â€”ng/mL as the Cutoff for Prostate Cancer Screening in Primary Care. <i>Urology</i> , 2016, 96, 116-120.	1.0	11
282	The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality. <i>Journal of Urology</i> , 2017, 197, 1060-1067.	0.4	10
283	What does prostate-specific antigen recurrence mean?. <i>Current Urology Reports</i> , 2000, 1, 28-35.	2.2	9
284	High-Grade Prostatic Adenocarcinoma Present in a Single Biopsy Core is Associated With Increased Extraprostatic Extension, Seminal Vesicle Invasion, and Positive Surgical Margins at Prostatectomy. <i>Urology</i> , 2012, 79, 863-868.	1.0	9
285	Predicting the Risk of Nonâ€”organ-confined Prostate Cancer When Perineural Invasion Is Found on Biopsy. <i>Urology</i> , 2014, 83, 1117-1121.	1.0	9
286	Prostate-specific antigen as a marker of disease activity in prostate cancer. <i>Oncology</i> , 2002, 16, 1218-24; discussion 1224, 1227-8 passim.	0.5	9
287	Radical Retropubic and Perineal Prostatectomy. , 2012, , 2801-2829.e4.		8
288	Prostate cancer: Detection, staging, and treatment of localized disease. <i>Seminars in Roentgenology</i> , 1999, 34, 269-283.	0.6	7

#	ARTICLE	IF	CITATIONS
289	Evaluation of two mitochondrial DNA biomarkers for prostate cancer detection. <i>Cancer Biomarkers</i> , 2015, 15, 763-773.	1.7	7
290	Needle Biopsy of Recurrent Adenocarcinoma of the Prostate After Radical Prostatectomy. <i>Modern Pathology</i> , 2000, 13, 521-527.	5.5	6
291	The role of free prostate-specific antigen in prostate cancer detection. <i>Current Urology Reports</i> , 2000, 1, 78-82.	2.2	6
292	Kinetics of tumor growth of prostate carcinoma estimated using prostate-specific antigen. <i>Urology</i> , 2005, 66, 577-581.	1.0	6
293	Reply to Juan Morote's Letter to the Editor re: Felix K. Chun, Alexandre de la Taille, Hendrik van Poppel, et al. Prostate Cancer Gene 3 (PCA3): Development and Internal Validation of a Novel Biopsy Nomogram. <i>Eur Urol</i> 2009;56:659-68. <i>European Urology</i> , 2010, 57, e2-e3.	1.9	6
294	Significance of preoperative PSA velocity in men with low serum PSA and normal DRE. <i>World Journal of Urology</i> , 2011, 29, 11-14.	2.2	6
295	Role of biobanking in urology: a review. <i>BJU International</i> , 2016, 118, 864-868.	2.5	6
296	Complications after open and robot-assisted radical prostatectomy and association with postoperative opioid use: an analysis of data from the PREVENTER trial. <i>BJU International</i> , 2021, 127, 190-197.	2.5	6
297	Prostate Cancer Tumor Markers. , 2012, , 2748-2762.e6.		6
298	Interim analysis of companion, prospective, phase II, clinical trials assessing the efficacy and safety of multi-modal total eradication therapy in men with synchronous oligometastatic prostate cancer. <i>Medical Oncology</i> , 2022, 39, 63.	2.5	6
299	Prostate-specific antigen and new serum biomarkers for evaluation of chemopreventive agents. <i>Urology</i> , 2001, 57, 132-136.	1.0	5
300	The role of prostate needle biopsy in evaluation of chemopreventive agents. <i>Urology</i> , 2001, 57, 191-193.	1.0	5
301	Risk Factors for Intraprostatic Incision into Malignant Glands at Radical Prostatectomy. <i>European Urology</i> , 2015, 68, 311-316.	1.9	5
302	Does sextant prostate biopsy provide adequate sampling for early detection of prostate cancer?. <i>Current Urology Reports</i> , 2000, 1, 245-245.	2.2	4
303	Docetaxel in androgen-independent prostate cancer: an update. <i>BJU International</i> , 2004, 94, 1209-1210.	2.5	4
304	Preoperative characteristics of men with unfavorable high-Gleason prostate cancer at radical prostatectomy. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2013, 31, 589-594.	1.6	4
305	Early Detection of Prostate Cancer Continues to Support Rational, Limited Screening. <i>Journal of Urology</i> , 2013, 190, 427-428.	0.4	4
306	Patterns of Pelvic Lymph Node Dissection at the Time of Radical Prostatectomy for Low-risk Men. <i>Urology</i> , 2017, 104, 143-149.	1.0	4

#	ARTICLE	IF	CITATIONS
307	Contemporary Assessment of the Most Cited Clinical, Basic Science, and Guidelines Papers in Urology: A Reference for Urology Journal Club. <i>Urology</i> , 2021, 149, 58-69.	1.0	4
308	MOLECULAR STAGING OF MEN WITH SEMINAL VESICLE INVASION AND NEGATIVE LYMPH NODES AT RADICAL PROSTATECTOMY. <i>Journal of Urology</i> , 1999, , 235.	0.4	4
309	Gleason Score 7 Prostate Cancer on Needle Biopsy: Is the Prognostic Difference in Gleason Scores 4 3 and 3 4 Independent of the Number of Involved Cores?. <i>Journal of Urology</i> , 2002, , 2440-2442.	0.4	4
310	Percent Free Prostate Specific Antigen in the Total Prostate Specific Antigen 2 to 4 ng./ml. Range Does Not Substantially Increase the Number of Biopsies Needed to Detect Clinically Significant Prostate Cancer Compared to the 4 to 10 ng./ml. Range. <i>Journal of Urology</i> , 2002, , 504-508.	0.4	4
311	Comparison of Total Prostate-Specific Antigen and Derivative Levels in a Screening Population of Black, White, and Korean-American Men. <i>Clinical Prostate Cancer</i> , 2003, 2, 173-176.	2.1	3
312	Re: "Obesity and hormone-dependent tumors: cohort and co-twin control studies based on the Swedish twin registry". <i>International Journal of Cancer</i> , 2006, 118, 785-785.	5.1	3
313	A prospective comparative study of routine versus deferred pelvic drain placement after radical prostatectomy: impact on complications and opioid use. <i>World Journal of Urology</i> , 2021, 39, 1845-1851.	2.2	3
314	A novel method for detection of exfoliated prostate cancer cells in urine by RNA in situ hybridization. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 220-232.	3.9	3
315	Effect of Erythropoietin on Erectile Function after Radical Prostatectomy: The ERECT Randomized Clinical Trial. <i>Journal of Urology</i> , 2021, 205, 1681-1688.	0.4	3
316	Heredity and prostate cancer: A study of World War II veteran twins. <i>Prostate</i> , 1997, 33, 240-245.	2.3	3
317	PREDICTION OF POST-RADICAL PROSTATECTOMY PATHOLOGICAL OUTCOME FOR STAGE T1c PROSTATE CANCER WITH PERCENT FREE PROSTATE SPECIFIC ANTIGEN: A PROSPECTIVE MULTICENTER CLINICAL TRIAL. <i>Journal of Urology</i> , 1999, , 1346-1351.	0.4	3
318	VALIDATION OF PARTIN TABLES FOR PREDICTING PATHOLOGICAL STAGE OF CLINICALLY LOCALIZED PROSTATE CANCER. <i>Journal of Urology</i> , 2000, , 1591-1595.	0.4	3
319	Prediction of Pathological Stage in Patients with Clinical Stage T1c Prostate Cancer: The New Challenge. <i>Journal of Urology</i> , 2002, , 100-104.	0.4	3
320	Best of the 2017 AUA Annual Meeting: Highlights From the 2017 American Urological Association Annual Meeting, May 12-16, 2017, Boston, MA. <i>Reviews in Urology</i> , 2017, 19, 169-179.	0.9	3
321	PCA3 Urinary Biomarker for Prostate Cancer. <i>Reviews in Urology</i> , 2010, 12, e205-6.	0.9	3
322	Know your nomograms. <i>BJU International</i> , 2014, 113, 849-849.	2.5	2
323	Risk factors for metastatic prostate cancer: A sentinel event case series. <i>Prostate</i> , 2017, 77, 1366-1372.	2.3	2
324	ISOLATED LOCAL RECURRENCE IS RARE AFTER RADICAL PROSTATECTOMY IN MEN WITH GLEASON 7 PROSTATE CANCER AND POSITIVE SURGICAL MARGINS: THERAPEUTIC IMPLICATIONS. <i>Journal of Urology</i> , 2001, , 864-866.	0.4	2

#	ARTICLE	IF	CITATIONS
325	PSA doubling time (PSADT) and proximal PSA value predict metastasis-free survival (MFS) in men with biochemically recurrent prostate cancer (BRPC) after radical prostatectomy (RP).. Journal of Clinical Oncology, 2017, 35, 5075-5075.	1.6	2
326	Best of the 2007 AUA Annual Meeting: Highlights from the 2007 Annual Meeting of the American Urological Association, May 19-24, 2007, Anaheim, CA. Reviews in Urology, 2007, 9, 133-54.	0.9	2
327	Genetic tests for prostate cancer. Reviews in Urology, 2013, 15, 208-9.	0.9	2
328	Best of the 2014 AUA Annual Meeting: Highlights From the 2014 American Urological Association Annual Meeting, May 16-21, 2014, Orlando, FL. Reviews in Urology, 2014, 16, 139-44.	0.9	2
329	Robotic Prostatectomy Diffusion Safety Concerns. JAMA Surgery, 2014, 149, 852.	4.3	1
330	In Reply to the Letter to the Editor from Raj et al.: Clinical Evidence Indicates Allogeneic Mesenchymal Stem Cells Do Not Pose a Significant Risk for Cancer Progression in the Context of Cell-Based Drug Delivery. Stem Cells Translational Medicine, 2019, 8, 739-740.	3.3	1
331	Molecular and immunohistochemical staging of men with seminal vesicle invasion and negative pelvic lymph nodes at radical prostatectomy. Cancer, 2000, 89, 2577-2586.	4.1	1
332	Clinical utility of indium 111-epsilonpromab pendetide immunoscintigraphy in the detection of early, recurrent prostate carcinoma after radical prostatectomy. Cancer, 2002, 94, 987-996.	4.1	1
333	DISEASE PROGRESSION FOLLOWING RADICAL PROSTATECTOMY IN MEN WITH GLEASON SCORE 7 TUMOR. Journal of Urology, 1998, , 97-100.	0.4	1
334	ABILITY OF THE 1992 AND 1997 AMERICAN JOINT COMMITTEE ON CANCER STAGING SYSTEMS FOR PROSTATE CANCER TO PREDICT PROGRESSION-FREE SURVIVAL AFTER RADICAL PROSTATECTOMY FOR STAGE T2 DISEASE. Journal of Urology, 2000, , 89-92.	0.4	1
335	The Role of Complexed Prostate-Specific Antigen in Prostate Cancer Screening. , 2008, , 29-41.		1
336	PSA doubling time (PSADT) <math>\leq 6</math> months to identify a subgroup of men with biochemically-recurrent prostate cancer (BRPC) after prostatectomy (RP) at highest risk of distant metastasis (dMET).. Journal of Clinical Oncology, 2016, 34, e16587-e16587.	1.6	1
337	Evolving Role of Pro-PSA as a New Serum Marker for the Early Detection of Prostate Cancer. Reviews in Urology, 2002, 4, 198-200.	0.9	1
338	Critical analysis of false elevations in PSA results reported with the abbott AxSYM assay. , 1999, 38, 79-80.		0
339	Management of patients with an increasing prostate-specific antigen after radical prostatectomy. Current Prostate Reports, 2004, 2, 12-20.	0.1	0
340	Re: Detailed Analysis of Patients with Metastasis to the Prostatic Anterior Fat Pad Lymph Nodes: A Multi-Institutional Study. Journal of Urology, 2014, 191, 559-561.	0.4	0
341	A Novel Approach for Performing Bone Marrow Aspiration at the Time of Radical Prostatectomy. Urology Case Reports, 2016, 6, 45-46.	0.3	0
342	Where it all Began. Journal of Urology, 2017, 197, S153.	0.4	0

#	ARTICLE	IF	CITATIONS
343	High $\alpha$ - $\mu$ ve. journal of applied laboratory medicine, The, 2018, 3, 333-335.	1.3	0
344	Cell cycle progression score and PTEN as prognostic factors for metastasis in intermediate- and high-risk prostate cancer overall, and in those who also received salvage radiotherapy.. Journal of Clinical Oncology, 2021, 39, 247-247.	1.6	0
345	The Clinical Management of Prostate Cancer $\hat{=}$ The Surgeon's Approach and Outcomes. , 2003, , 811-831.		0
346	Total, Complexed, and Free PSA Forms and Human Glandular Kallikrein 2. , 2004, , 15-36.		0
347	IL-3 PSA Update-2004. Japanese Journal of Urology, 2004, 95, 267.	0.1	0
348	Subfractions and Derivatives of Total Prostate-Specific Antigen in the Early Detection of Prostate Cancer. , 2009, , 79-95.		0
349	The natural history of progression to PSA recurrence and metastasis among at risk men following radical prostatectomy.. Journal of Clinical Oncology, 2014, 32, 5036-5036.	1.6	0
350	Combined DNA-methylation intensity and clinical risk score to stratify patients for high-grade disease.. Journal of Clinical Oncology, 2016, 34, 51-51.	1.6	0
351	Risk factors for metastatic prostate cancer: A sentinel event case series.. Journal of Clinical Oncology, 2017, 35, 235-235.	1.6	0
352	Cell cycle progression score and PTEN as prognostic factors for metastasis in intermediate and high-risk prostate cancer.. Journal of Clinical Oncology, 2019, 37, e16575-e16575.	1.6	0
353	The predictive capability of prostate-specific antigen kinetics. Reviews in Urology, 2006, 8, 41-3.	0.9	0
354	Advances in prostate cancer treatment: highlights from the 2nd international prostate cancer congress, st. Thomas, u.s. Virgin islands, july 17-20, 2002. Reviews in Urology, 2003, 5, 111-7.	0.9	0
355	Conflicting insights into the role of watchful waiting in the management of adenocarcinoma of the prostate. Reviews in Urology, 2006, 8, 232-4.	0.9	0
356	Best of the 2015 AUA Annual Meeting: Highlights From the 2015 American Urological Association Annual Meeting, May 15-19, 2015, New Orleans, LA. Reviews in Urology, 2015, 17, 179-89.	0.9	0